

## **Invitation to Presentation of Promore Pharma's Interim report for the second quarter 2019**

***STOCKHOLM, 23 August 2019 – Promore Pharma AB (publ) publishes its Interim report for the second quarter 2019 at 14.00 CET on 28 August 2019.***

The next day, 29 August, the company will host a webcast telephone conference at 10.00 CET, with President and CEO Jonas Ekblom and CFO Jenni Björnulfson. After the presentation there will be a Q&A session. The presentation will be held in English. The conference can be accessed via computer, tablet or telephone.

To join the web conference, please use the following link:  
<https://global.gotomeeting.com/join/494286021>

To join the telephone conference, please use one of the following numbers:

Sweden: +46 853 527 836

Denmark: +45 32 72 03 822

Finland: +358 923 17 0568

Norway: +47 23 16 23 30

Spain: +34 932 75 2004

UK: +44 20 3713 5028

Germany: +49 692 5736 7317

Use the access code 494 286 021 to join the meeting.

The telephone conference and the presentation material will be available on the company's website after the call; [www.promorepharma.com](http://www.promorepharma.com).

### **For additional information, please contact**

Jonas Ekblom, VD

Tel: [+46] 736 777 540

E-mail: [jonas.ekblom@promorepharma.com](mailto:jonas.ekblom@promorepharma.com)

Jenni Björnulfson, CFO

Tel: [+46] 708 55 38 05

E-mail: [jenni.bjornulfson@promorepharma.com](mailto:jenni.bjornulfson@promorepharma.com)

**Promore Pharma in brief**

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications where very few efficacious prescription pharmaceuticals are available, thus, addressing high unmet medical needs. Promore Pharma's two projects are in late stage clinical development phase and have a very strong safety profile since they are based on innate substances that are administered locally. The leading project, PXL01, that will be used for prevention of post-surgical adhesions and scars, is being prepared for clinical phase III-studies in patients undergoing tendon repair surgery in the hand. LL-37 has initiated a clinical phase IIb study in patients with venous leg ulcers (VLU). The product candidates can also be deployed for other indications, such as preventing dermal scarring, adhesions after other surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North.

*Promore Pharma's Certified Adviser is Redeye AB.*

Phone: [+46] 8 121 576 90

E-mail: [Certifiedadviser@redeye.se](mailto:Certifiedadviser@redeye.se)